ENTRESTOâ„¢ (sacubitril/valsartan) for the Management of Heart Failure
March 31st 2016ENTRESTOâ„¢ (sacubitril/valsartan) tablets 24/26 mg, 49/51 mg, 97/103 mg, from Novartis Pharmaceuticals Corporation, are a combination of an angiotensin receptor blocker and a novel neprilysin inhibitor, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (New York Heart Association class II through IV) and reduced ejection fraction.
Navigating the Complexities of Pharmacy Reimbursement: Will We Ever Reach Transparency?
March 23rd 2016Evolution in the pharmacy reimbursement system represents a crucial component toward stabilizing costs and providing fair margins for pharmacy sustainability, particularly in rural and underserved areas.
Independent Pharmacy's Future: Goal-Setting Is Key for Solvency
March 18th 2016Establishing a competitive edge against large, national retail pharmacy chains and mail order pharmacies has been one of the most significant challenges facing independent pharmacies for many years.